Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials
International Journal of Molecular Sciences · 14.07.2023 · 24 (14) · 11450
DOI: 10.3390/ijms241411450 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.07.2023. Verfasst von Keren Esther Kristina Mantik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Research Center for Controlling Intercellular Communication, College of Medicine, Inha University, Incheon 22212, Republi…. Hauptthemen laut MEDLINE: Insulin Resistance, Alzheimer Disease, Insulins. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education.
Themen: Demenz
Abstract (Originalsprache)
Insulin resistance as a hallmark of type 2 DM (T2DM) plays a role in dementia by promoting pathological lesions or enhancing the vulnerability of the brain. Numerous studies related to insulin/insulin-like growth factor 1 (IGF-1) signaling are linked with various types of dementia. Brain insulin resistance in dementia is linked to disturbances in Aβ production and clearance, Tau hyperphosphorylation, microglial activation causing increased neuroinflammation, and the breakdown of tight junctions in the blood–brain barrier (BBB). These mechanisms have been studied primarily in Alzheimer’s disease (AD), but research on other forms of dementia like vascular dementia (VaD), Lewy body dementia (LBD), and frontotemporal dementia (FTD) has also explored overlapping mechanisms. Researchers are currently trying to repurpose anti-diabetic drugs to treat dementia, which are dominated by insulin sensitizers and insulin substrates. Although it seems promising and feasible, none of the trials have succeeded in ameliorating cognitive decline in late-onset dementia. We highlight the possibility of repositioning anti-diabetic drugs as a strategy for dementia therapy by reflecting on current and previous clinical trials. We also describe the molecular perspectives of various types of dementia through the insulin/IGF-1 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Research Center for Controlling Intercellular Communication, College of Medicine, Inha University, Incheon 22212, Republic of Korea.
- Program in Biomedical Science and Engineering, Inha University, Incheon 22212, Republic of Korea.
- Department of Kinesiology, College of Arts and Sports, Inha University, Incheon 22212, Republic of Korea.
ORCID-Profile: Hyo-Bum Kwak, Dong-Ho Park, Ju-Hee Kang
Förderung
- National Research Foundation of Korea
- Ministry of Education
Zitieren
APA
Mantik, K. E. K., Kim, S., Gu, B., Moon, S., Kwak, H. B., Park, D. H., & Kang, J. H. (2023). Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials. International Journal of Molecular Sciences, 24(14), 11450. https://doi.org/10.3390/ijms241411450
Vancouver
Mantik KEK, Kim S, Gu B, Moon S, Kwak HB, Park DH, et al. Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials. International Journal of Molecular Sciences. 2023;24(14):11450. doi:10.3390/ijms241411450
BibTeX
@article{Mantik2023,
author = {Mantik, Keren Esther Kristina and Kim, Sujin and Gu, Bonsang and Moon, Sohee and Kwak, Hyo-Bum and Park, Dong-Ho and Kang, Ju-Hee},
title = {Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11450},
doi = {10.3390/ijms241411450}
}
EUVIMED